Literature DB >> 7042060

Non-Hodgkin's lymphoma in Manitoba, 1968-77: the impact of chemotherapy.

L Deonarine, B H Weinerman, B K MacDougall, S Kemel.   

Abstract

Manitoba tumour registry data for patients with non-Hodgkin's lymphoma diagnosed between 1968 and 1977 inclusive who were given chemotherapy were reviewed. The Rappaport classification of these tumours enabled general pathologists in the province to distinguish three main prognostic groups. Combination chemotherapy improved survival significantly more than single-agent chemotherapy only for the patients with diffuse histiocytic lymphoma, not for those with diffuse poorly differentiated lymphocytic lymphoma or the more favourable histologic types of non-Hodgkin's lymphoma--diffuse well differentiated lymphocytic and nodular poorly differentiated lymphocytic. For the last two types, therefore, the more intensive chemotherapy is not justified.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7042060      PMCID: PMC1863096     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN: 0008-4409            Impact factor:   8.262


  13 in total

1.  Non-Hodgkin's lymphoma: patterns of relapse from complete remission after combination chemotherapy.

Authors:  P S Schein; B A Chabner; G P Canellos; R C Young; V T DeVita
Journal:  Cancer       Date:  1975-02       Impact factor: 6.860

2.  Maximum utilization of the life table method in analyzing survival.

Authors:  S J CUTLER; F EDERER
Journal:  J Chronic Dis       Date:  1958-12

3.  Statistical aspects of the analysis of data from retrospective studies of disease.

Authors:  N MANTEL; W HAENSZEL
Journal:  J Natl Cancer Inst       Date:  1959-04       Impact factor: 13.506

4.  Follicular lymphoma; a re-evaluation of its position in the scheme of malignant lymphoma, based on a survey of 253 cases.

Authors:  E B HICKS; H RAPPAPORT; W J WINTER
Journal:  Cancer       Date:  1956 Jul-Aug       Impact factor: 6.860

5.  No initial therapy for stage III and IV non-Hodgkin's lymphomas of favorable histologic types.

Authors:  C S Portlock; S A Rosenberg
Journal:  Ann Intern Med       Date:  1979-01       Impact factor: 25.391

Review 6.  The use of drugs in combination for the treatment of cancer: rationale and results.

Authors:  V T DeVita; P S Schein
Journal:  N Engl J Med       Date:  1973-05-10       Impact factor: 91.245

7.  Advanced diffuse histiocytic lymphoma, a potentially curable disease.

Authors:  V T DeVita; G P Canellos; B Chabner; P Schein; S P Hubbard; R C Young
Journal:  Lancet       Date:  1975-02-01       Impact factor: 79.321

8.  Comparison of combined and single-agent chemotherapy in non-Hodgkin's lymphoma of favourable histological type.

Authors:  T A Lister; M H Cullen; M E Beard; R L Brearley; J M Whitehouse; P F Wrigley; A G Stansfeld; S B Sutcliffe; J S Malpas; D Crowther
Journal:  Br Med J       Date:  1978-03-04

9.  Combination chemotherapy in non-Hodgkin's lymphoma: results of long-term followup.

Authors:  T Anderson; R A Bender; R I Fisher; V T DeVita; B A Chabner; C W Berard; L Norton; R C Young
Journal:  Cancer Treat Rep       Date:  1977-09

10.  BCNU with and without cyclophosphamide, vincristine, and prednisone (COP) and cycle-active therapy in non-Hodgkin's lymphoma.

Authors:  J R Durant; R A Gams; A A Bartolucci; R F Dorfman
Journal:  Cancer Treat Rep       Date:  1977-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.